{"id":"W4412732609","doi":"10.1136/bmjopen-2025-099577","title":"Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK","year":2025,"lang":"en","type":"article","venue":"BMJ Open","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"NIHR Cambridge Biomedical Research Centre; Cambridge Centre for Parkinson-Plus; Medical Research Council; National Institute for Health and Care Research; Wellcome Trust","keywords":"Progressive supranuclear palsy; Medicine; Atomoxetine; Apathy; Placebo; Montreal Cognitive Assessment; Tolerability; Randomized controlled trial; Clinical trial; Physical therapy; Cognition; Psychiatry; Internal medicine; Adverse effect; Disease; Attention deficit hyperactivity disorder; Pathology; Methylphenidate; Alternative medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001814979,0.001722113,0.003968242,0.0004026316,0.0005063422,0.0009907967,0.001086332,0.002491274,0.00909467],"category_scores_gemma":[0.001737649,0.0009361691,0.001756263,0.000363834,0.001103743,0.0007639581,0.0004526631,0.002329401,0.001267706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009154401,"about_ca_system_score_gemma":0.001830565,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003172911,"about_ca_topic_score_gemma":0.008847276,"domain_scores_codex":[0.9992726,0.000372644,0.00006136345,0.0001060216,0.00005742198,0.0001298823],"domain_scores_gemma":[0.9991968,0.000206698,0.0001786265,0.0000508674,0.00007479278,0.0002921129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837739,0.004897688,0.0002728088,0.001073924,0.0005285176,0.00005487094,0.00005454709,0.0001111017,0.001602377,0.00005725816,0.0005477061,0.007025225],"study_design_scores_gemma":[0.9648513,0.03363678,0.0009137806,0.00002879314,0.0001492741,0.00001443732,0.00001233824,0.00007088055,0.00007312127,0.00003012067,0.0002125935,0.000006607654],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9704646,0.005125562,0.0005342495,0.0008012733,0.0008373322,0.01710103,0.002005883,0.0001446361,0.002985322],"genre_scores_gemma":[0.964586,0.005357436,0.001885399,0.00153867,0.0006193845,0.01755225,0.001863035,0.00002539173,0.006572333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00909467,"threshold_uncertainty_score":0.03042477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1520146610218427,"score_gpt":0.4879409402558362,"score_spread":0.3359262792339934,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}